Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS
Clinical trial NCT03920657 · TERMINATED
Trial details
- NCT number
- NCT03920657
- Sponsor
- Fondazione Italiana Sindromi Mielodisplastiche-ETS
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-04
- Primary completion
- 2020-10-06
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.